Dominari Holdings Inc. (NASDAQ:DOMH - Get Free Report) CEO Anthony Hayes acquired 3,944 shares of the firm's stock in a transaction on Thursday, April 4th. The shares were acquired at an average price of $2.62 per share, with a total value of $10,333.28. Following the completion of the purchase, the chief executive officer now owns 102,748 shares of the company's stock, valued at $269,199.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Dominari Trading Down 9.9 %
Shares of DOMH stock opened at $2.83 on Tuesday. The company has a market capitalization of $16.78 million, a PE ratio of -0.64 and a beta of 0.91. The firm has a fifty day simple moving average of $2.24 and a 200-day simple moving average of $2.21. Dominari Holdings Inc. has a twelve month low of $1.76 and a twelve month high of $3.76.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in DOMH. BlackRock Inc. purchased a new position in shares of Dominari in the second quarter valued at $219,000. Geode Capital Management LLC bought a new position in Dominari during the 2nd quarter valued at $126,000. Renaissance Technologies LLC bought a new position in Dominari during the 2nd quarter valued at $109,000. State Street Corp bought a new position in Dominari during the 2nd quarter valued at $58,000. Finally, Citadel Advisors LLC bought a new position in Dominari during the 2nd quarter valued at $52,000. 42.48% of the stock is currently owned by hedge funds and other institutional investors.
About Dominari
(
Get Free Report)
Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years
From Banyan Hill Publishing | Ad
If you think AI is big, then you have got to check out something I call Imperium…
By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)
Watch my video for all of the details
Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
